Kadian Revenue Jump Offsets Alpharma's Loss Of Gabapentin Exclusivity
This article was originally published in The Pink Sheet Daily
Increased sales and marketing efforts have driven the extended-release morphine's weekly prescription rates above 10,000.
You may also be interested in...
Alpharma's Kadian joins the list of extended-release opioid analgesics for which FDA has requested expanded label warnings regarding alcohol following the withdrawal of Palladone. Alpharma is planning to conduct in vivo bioequivalence studies with Kadian to assess the clinical implication of the in vitro data.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.